XML 112 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:        
Net loss $ (11,353,000) $ (16,386,000) $ (28,962,000) $ (19,445,000)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation of property and equipment 28,000 30,000 39,000 38,000
Redeemable warrants valuation adjustment     (35,000)
Gain on sale of fixed assets     (18,000)
Abandonment and expiration of patents and trademark rights 46,000 14,000 14,000
Amortization of patent and trademark rights 154,000 150,000 199,000 218,000
Non-cash lease expense     287,000 (680,000)
Changes in right of use assets 226,000 151,000    
Loss from sale of income tax operating losses (900,000) 197,000
Equity-based compensation 490,000 182,000 243,000 954,000
Loss (gain) on sale of marketable investments (95,000) 201,000 (200,000) 1,679,000
Loss on issuance of warrants 458,000    
Amortization of financial obligation 232,000    
Change in assets and liabilities:        
Other receivables (9,000)    
Funds receivable from New Jersey operating loss sales 1,181,000 1,676,000 492,000 (35,000)
Prepaid expenses and other current assets (63,000) 192,000 153,000 (151,000)
Lease liability (231,000) (136,000) (274,000) 688,000
Other assets (1,028,000) (486,000) (83,000)
Accounts payable (179,000) 2,411,000 6,066,000 179,000
Accrued expenses (799,000) 915,000 1,180,000 368,000
Net cash used in operating activities (10,933,000) (11,509,000) (21,267,000) (16,108,000)
Cash flows from investing activities:        
Proceeds from sale of marketable investments 1,597,000 924,000 1,299,000 10,083,000
Purchase of marketable investments (158,000) (1,155,000) (1,593,000) (2,724,000)
Purchase of property and equipment (18,000) (10,000) (86,000)
Proceeds from sale of property and equipment     47,000 3,900,000
Purchase of patent and trademark rights (419,000) (377,000) (585,000) (185,000)
Net cash (used in) provided by investing activities 1,002,000 (618,000) (832,000) 10,988,000
Cash flows from financing activities:        
Proceeds from sale of stock, net of issuance costs 860,000 338,000 485,000 80,000
Proceeds from note payable, net of issuance costs 2,500,000    
Proceeds from issuance of equity warrants 2,047,000    
Net cash provided by financing activities 5,407,000 338,000 485,000 80,000
Net decrease in cash and cash equivalents (4,524,000) (11,789,000) (21,614,000) (5,040,000)
Cash and cash equivalents at beginning of year 5,439,000 27,053,000 27,053,000 32,093,000
Cash and cash equivalents at end of year 915,000 15,264,000 5,439,000 27,053,000
Supplemental disclosures of non-cash investing and financing cash flow information:        
Operating lease-Right of Use Assets (3,000) 49,000    
Unrealized gain (loss) on marketable investments 373,000 (71,000) 376,000 (928,000)
Conversion of Series B preferred 6,000 7,000 19,000
Conversion of note payable interest into shares $ 175,000    
Operating lease liability arising from obtaining right of use asset     $ 73,000 $ 736,000